Dec. 24 at 11:42 PM
$EQ With Abivax more than likely to sell this next and for huge dollars if phase 1 data is positive. Morphic sold to Lilly for 3.2 billion Phase 2A, Prometheus to Merck for 10.8 billion Phase 2A, and Protagonist to J @ J for 900 million at preclinical. This is why heavyweights in the Biotech space ADAR1 and Janus gave EQ so much money. They know exactly what there doing and undoubtedly have done thorough due diligence. Very strong potential for a massive payday in 2027. EQ will have suitors lined up right after Phase 1.
